These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 17558264)

  • 21. The overactive bladder syndrome: treating patients on an individual basis.
    Cardozo L
    BJU Int; 2007 Jun; 99 Suppl 3():1-7. PubMed ID: 17488366
    [No Abstract]   [Full Text] [Related]  

  • 22. Lower urinary tract symptoms (LUTS) in men: thinking beyond the prostate.
    Elsamra S; Ellsworth PS
    Med Health R I; 2010 Feb; 93(2):53-6. PubMed ID: 20329627
    [No Abstract]   [Full Text] [Related]  

  • 23. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
    Schneider T; Marschall-Kehrel D; Hanisch JU; Michel MC
    Int J Clin Pract; 2010 Aug; 64(9):1287-93. PubMed ID: 20500534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Overactive bladder. When it's pressing, immediate help is indicated].
    Widhalm S
    MMW Fortschr Med; 2008 May; 150(20):44-5. PubMed ID: 18605642
    [No Abstract]   [Full Text] [Related]  

  • 26. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.
    Irwin DE; Kopp ZS; Agatep B; Milsom I; Abrams P
    BJU Int; 2011 Oct; 108(7):1132-8. PubMed ID: 21231991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medical treatment of voiding problems in men].
    Andersen JT; Nordling J; Walter S
    Ugeskr Laeger; 2007 May; 169(20):1892-4. PubMed ID: 17553364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of overactive bladder].
    Hunskår S
    Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2029-30. PubMed ID: 16100546
    [No Abstract]   [Full Text] [Related]  

  • 29. Overactive bladder pharmacotherapy: what does the future hold?
    Dmochowski RR
    BJU Int; 2007 Jun; 99 Suppl 3():13-6. PubMed ID: 17488368
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacologic management of bladder dysfunction in adult women.
    O'Dell K
    J Obstet Gynecol Neonatal Nurs; 2014; 43(2):253-63. PubMed ID: 24502427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower urinary tract symptoms in women.
    Milsom I
    Curr Opin Urol; 2009 Jul; 19(4):337-41. PubMed ID: 19444118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A journey to continence: a case study of overactive bladder syndrome.
    Spilde NL
    Urol Nurs; 2008 Jun; 28(3):209-12. PubMed ID: 18605514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the overactive bladder in women and men.
    Kowalczyk J
    J Gend Specif Med; 2003; 6(4):25-9. PubMed ID: 14714447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years.
    Malmsten UG; Molander U; Peeker R; Irwin DE; Milsom I
    Eur Urol; 2010 Jul; 58(1):149-56. PubMed ID: 20356669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Darifenacin in the treatment of overactive bladder.
    Parsons M; Robinson D; Cardozo L
    Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Substantiation of the duration of m-cholinolytics administration in conservative treatment of hyperactive urinary bladder].
    Danilov VV; Vol'nykh IIu; Danilova TI; Vodop'ianova OA; Kudriakova NA
    Urologiia; 2006; (5):71-4. PubMed ID: 17444156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overactive bladder symptoms in women: current concepts in patient management.
    Easton WA
    Can J Urol; 2010 Feb; 17 Suppl 1():12-7. PubMed ID: 20170596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.
    Andersson KE; Chapple CR; Cardozo L; Cruz F; Hashim H; Michel MC; Tannenbaum C; Wein AJ
    Curr Opin Urol; 2009 Jul; 19(4):380-94. PubMed ID: 19448545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.